Advances in the treatment of systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a chronic systemic inflammatory rheumatic disease and treatment is based on the use of anti-inflammatory/immunosuppressive medications. Basic medications in the treatment of SLE are glucocorticoids and antimalarials. In certain groups of patients who have certain organs affected, different cytostatic / immunomodulatory medications are applied, such as cyclophosphamide, azathioprine, mycophenolate mofetil or cyclosporin A. Agents that act primarily on B lymphocytes are likely to play a significant role. Treatment of patients with SLE has an anti-inflammatory and symptomatic component. Anti-inflammatory treatment always has an induction phase in which achievement of inflammation remission is seeked. After appeasing inflammation, the sustaining phase of treatment follows, which maintains the impact achieved. Symptomatic therapy heals the affected organs and cures and prevents the adverse effects of anti-inflammatory drugs.
Key words:
systemic lupus erythematosus; treatment
OGLASI
